Plasma Proteome Profiles for MASLD Biomarker Discovery in Type 2 Diabetes Patients

176 differentially expressed plasma proteins were identified in a study of 84 type 2 diabetes patients with and without metabolic dysfunction-associated steatotic liver disease. The dataset, authored by Hua Ji and updated in April 2026, focuses on the novel biomarker XPNPEP3, which was significantly downregulated and validated via ELISA and immunohistochemistry.

Use Cases

• Validate the diagnostic performance of XPNPEP3 for MASLD based on ROC analysis results.
• Investigate protein correlations with clinical indicators like diabetes duration and triglyceride levels.
• Explore the pathophysiology linking T2DM and MASLD based on hepatic protein expression data.
• Develop non-invasive diagnostic models combining biomarker levels with BMI and diabetes duration.

Strengths

• Includes validation results from an expanded cohort of 84 patients.
• Proteomic analysis identified 176 differentially expressed proteins.
• Biomarker findings were confirmed at the tissue level via immunohistochemistry.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small at 3.0 MB, suggesting limited raw data volume.

Provenance

Source

figshare, author Hua Ji.

Collection Method

Plasma samples analyzed via data-independent acquisition mass spectrometry and validated with enzyme-linked immunosorbent assay.

Time Range

null

Freshness

Last updated 2026-04-13 13:58:43; freshness should be verified.

Geography

null